DISCLOSURES

This activity is jointly provided by Northwest Portland Area Indian Health Board and Cardea

Cardea Services is approved as a provider of continuing nursing education by Montana Nurses Association, an accredited approver with distinction by the American Nurses Credentialing Center's Commission on Accreditation.

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Institute for Medical Quality/California Medical Association (IMQ/CMA) through the joint providership of Cardea and Northwest Portland Area Indian Health Board. Cardea is accredited by the IMQ/CMA to provide continuing medical education for physicians.

Cardea designates this live web-based training for a maximum of 1 AMA PRA Category 1 Credit(s)[™]. Physicians should claim credit commensurate with the extent of their participation in the activity.





DISCLOSURES

COMPLETING THIS ACTIVITY

Upon successful completion of this activity 1 contact hour will be awarded

Successful completion of this continuing education activity includes the following:

- Attending the entire CE activity;
- Completing the online evaluation;
- Submitting an online CE request.

Your certificate will be sent via email

If you have any questions about this CE activity, contact Michelle Daugherty at <u>mdaugherty@cardeaservices.org</u> or (206) 447-9538



CONFLICT OF INTEREST

Paulina Deming is on an advisory committee for Gilead.

None of the other planners or presenters of this CE activity have any relevant financial relationships with any commercial entities pertaining to this activity.



Acknowledgement

This presentation is funded in part by:

The Indian Health Service HIV Program and The Secretary's Minority AIDS Initiative Fund





Opioid Substitution Therapy and the HCV-Provider

Aaron Skiles, DNP, C-FNP UNM Sandoval Regional Medical Center




Objectives

- Discuss the association of the opioid crisis and the HCV epidemic.
- Understand the benefits of opioid substitution therapy on reduction of HCV transmission.
- Identify options for further training and education on buprenorphine



Opioid Deaths

• From 2002 to 2015, there was a 2.8-fold increase in the total number of deaths.









Opioid Deaths

 From 2002-2015, benzodiazepine deaths involving opioids increased two fold more than those not involving opioids.





- Of 34 US states and territories reporting to CDC in both 2006 and 2012, 30 (88%) reported higher incidence of acute hepatitis C in 2012 compared to 2006 among young persons.
- 15% had increases of 100%–199%, whereas
 50% had increases of ≥200%.
- The 5 states with the most cases in 2012 were Kentucky, Tennessee, Georgia, Indiana, and Florida.





What Could Have Prevented This?

- Syringe Exchange Programs
- Improved opioid prescribing
- Naloxone (overdose reversal)
- Opioid Substitution Therapy (OST
- Medication-Assisted Therapy (MAT)



The NEW ENGLAND JOURNAL of MEDICINE

HOME ARTICLES & MULTIMEDIA * ISSUES * SPECIALTIES & TOPICS * FOR AUTHORS * CME >



Perspective

Medication-Assisted Therapies — Tackling the Opioid-Overdose Epidemic

Nora D. Volkow, M.D., Thomas R. Frieden, M.D., M.P.H., Pamela S. Hyde, J.D., and Stephen S. Cha, M.D. N Engl J Med 2014; 370:2063-2066 | May 29, 2014 | DOI: 10.1056/NEJMp1402780

Share: 🛐 💌 💱 🛅 🛃

Article References Citing Articles (200) Metrics

The rate of death from overdoses of prescription opioids in the United States more than quadrupled between 1999 and 2010 (see graph), far exceeding the combined death toll

between 1999 and 2010 (see graph), far exceeding the combined death foil from cocaine and heroin overdoses.¹ In 2010 alone, prescription opioids were involved in 16,651 overdose deaths, whereas heroin was implicated in 3036. Some 82% of the deaths due to prescription opioids and 92% of those due to heroin were classified as unintentional, with the remainder being attributed predominantly to suicide or "undetermined intent."

Rates of emergency department visits and substance-abuse treatment admissions related to prescription opioids have also increased markedly. In 2007, prescription-opioid abuse cost insurers an estimated \$72.5 billion — a substantial increase over previous years.² These health and economic costs are similar to those associated with other chronic diseases such as asthma and HIV infection.



Opioid Sales, Admissions for Opioid-Abuse Treatment, and Deaths Due to Opioid Overdose in the United States, 1999 -2010.



What About Rehab?

- Abstinence-based programs:
 Greater than 80% relapse rate
- Acute Detox programs, stabilization only:
 - 40-60% relapse rate



Opioid Substitution Therapy (OST)

- Methadone—Only administered for Opioid Use Disorder in a federallycertified Opioid Treatment program.
- Buprenorphine –Routine office prescription if prescriber obtains a "waiver" DEA X-license
- Naltrexone—Opioid Use disorder treatment no restrictions (PO/IM)
- Naloxone– Overdose reversal, no restrictions (SC, IM, Intranasal)
- Only 34% of patients receive medication-assisted therapy. (Cochrane Review)



What is Our Role?

- Contain and cure an epidemic.
- WHO 2016-2021 Pathway to Elimination:
 - Improving injection safety and infection prevention to reduce new cases of hepatitis B and C
- Continued expansion of role of primary care clinician
- OST may reduce risk of HCV infection by 50-76%
- OST reduction in HIV infection, 64%
- Needle syringe programs in Europe: 76% reduction in HCV acquisition risk. (Cochrane Review)



Buprenorphine Training

- MD: 8 hour training
- NP/PA: 24 hour training
- Max 30 pts in year one, 100 patients thereafter
- Advantages
 - Eliminates need to visit specialized treatment clinics, wider availability.
 - Covered by Medicaid







Discussion



References

- https://www.drugabuse.gov/related-topics/trends-statistics/overdose-death-rates
- <u>https://www.asam.org/</u>
- <u>https://www.samhsa.gov/</u>
- Volkow, N., Frieden, T., Hyde, P., & Cha, S. (2014). Medication-Assisted Therapies—Tackling the Opioid-Overdose Epidemic. *New England Journal of Medicine*. *370:2063-2066*.
- Platt, L., Minozzi, S., Reed, J., Vickerman, P., Hagan, H., French, C., . . . Hickman, M. (2017). Needle syringe programmes and opioid substitution therapy for preventing hepatitis C transmission in people who inject drugs. *Cochrane Database of Systematic Reviews*.



Evaluation and Certificates

 Please use the link or QR code below to complete the learner evaluation. This link will also be emailed to you within a few days.
 Please check your junk and spam email folders if you don't receive it.

http://sgiz.mobi/s3/Nov-GP-ECHO

